-
CTN 173: Vaccination before treatment interruption
A pilot study to determine the impact of therapeutic HIV vaccination followed by a scheduled interruption of antiretroviral therapy on HIV-specific immune function and virologic rebound in patients with prolonged viral suppression: Trial results
-
CTN 167: Options with antiretrovirals (OPTIMA)
A tri-national (Canada, UK, USA) randomized, controlled trial to determine the optimal management of patients with HIV infection for whom first and second-line highly active antiretroviral therapy has failed
-
CTN 164: Treatment Interruption
A Prospective Randomized Trial of Structured Treatment Interruption (STI) Followed by the Initiation of a New Antiretroviral Regimen vs. Immediate Switching to a New Antiretroviral Regimen in HIV-Infected Patients Experiencing Virologic Failure on HAART
-
CTN 161: Simplified Protease Inhibitor Trial (SPRINT)
An International, Open-Label, Randomized, Multicentre Study to Evaluate the Antiviral Effect, Tolerability, Safety and Pharmacokinetics of Fortovase (saquinavir SGC) and Norvir (ritonavir) QD vs. Crixivan (indinavir) and Norvir (ritonavir) BID in HIV-Infected Patients
-
CTN 160: The Double Non-Nucleoside Study (2NN Study)
An Open-Label, Comparative Study to Evaluate the Antiviral Efficacy and Safety of Nevirapine and Efavirenz or Both Drugs Combined in Combination with d4T and 3TC. (The 2NN or Double Non-Nucleoside Study): Trial results
-
CTN 158: The CpG ODN 7909 as an Adjuvant and Immune Modulator
Phase I Safety and Immunogenicity Study of CpG ODN 7909 as an Immune Modulator and Adjuvant to Engerix®-B Vaccine in Haart-Treated, HIV-Positive Patients: Trial results
-
CTN 151: Multiple Drug Rescue Therapy
A Pilot Study Comparing Two Modalities of Multiple Drug Rescue Therapy (MDRT) among Pre-Treated, HIV-1 Infected Individuals – Full versus Sensitivity-Based MDRT Protocol: Trial results
-
CTN 149: Two PIs versus Efavirenz, with Two NRTIs
Open-Label, Randomized, Multicenter Study to Evaluate Fortovase® (Saquinavir SGC) QD, Norvir® (Ritonavir) QD plus Two NRTIs Vs. SustivaTM (Efavirenz) QD plus Two NRTIs in HIV-Infected Patients: Trial results
-
CTN 147: Early versus delayed pneumococcal vaccination
A pilot study assessing the efficacy of pneumococcal vaccine in HIV patients: delayed versus immediate immunization: Trial results
-
CTN 145: rIL-2 to slow progression of HIV (SILCAAT)
A Phase III, multicentre, randomized study of the biological and clinical efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with low CD4+ counts under active antiretroviral therapy(SILCAAT): Trial results
-
CTN 143: Twice Daily Indinavir plus Ritonavir
An Open-Label, Randomized, 48-Week Study to Compare the Safety, Tolerability, and Surrogate Marker Activity of an Indinavir Sulfate (800 mg q8h) Regimen versus BID Indinavir Sulfate (800 mg q12h) plus Ritonavir (100 mg q12h) Regimen in HIV-Infected Individuals Having Previously Achieved Viral Load Suppression below the Limit of Detection with a Triple Antiretroviral Treatment Regimen…
-
CTN 131: ddI, d4T and DMP with or without Hydroxyurea (3D Study)
A Randomized Placebo-Controlled Study of the Safety and Efficacy of Efavirenz (DMP), Didanosine and Stavudine in Combination with or without Hydroxyurea in Antiretroviral-Naïve or -Experienced, HIV-Infected Patients:
Careers
Interested in joining our team? Here are the current career opportunities with the CTN+ and our collaborators. For Fellowship opportunities, please visit our Postdoctoral Fellowship program page.v
Learn More